Mga Batayang Estadistika
| CIK | 739944 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| February 11, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Medtox Scientific, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 584977201 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| August 21, 2012 |
Form 15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 1-11394 MEDTOX Scientific, Inc. (Exact name of registrant as specifi |
|
| August 6, 2012 |
- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 Post-Effective Amendment No. 1 to Form S-8 As filed with the Securities and Exchange Commission on August 6, 2012 Registration No. 333-24371 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MEDTOX SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware |
|
| August 6, 2012 |
- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 Post-Effective Amendment No. 1 to Form S-8 As filed with the Securities and Exchange Commission on August 6, 2012 Registration No. 333-49456 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MEDTOX SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware |
|
| August 6, 2012 |
- POST EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 Post Effective Amendment No. 1 to Form S-3 As filed with the Securities and Exchange Commission on August 6, 2012 Registration No. 333-44942 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MEDTOX SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware |
|
| August 6, 2012 |
- POST EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 Post Effective Amendment No. 1 to Form S-3 As filed with the Securities and Exchange Commission on August 6, 2012 Registration No. 333-18547 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MEDTOX SCIENTIFIC, INC. (f/k/a EDITEK, INC.) (Exact name of registrant as specified in i |
|
| August 6, 2012 |
- POST EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 Post Effective Amendment No. 1 to Form S-3 As filed with the Securities and Exchange Commission on August 6, 2012 Registration No. 333-45057 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MEDTOX SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware |
|
| August 6, 2012 |
- POST EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 Post Effective Amendment No. 1 to Form S-3 As filed with the Securities and Exchange Commission on August 6, 2012 Registration No. 333-117198 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MEDTOX SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware |
|
| August 6, 2012 |
- POST EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 Post Effective Amendment No. 1 to Form S-1 As filed with the Securities and Exchange Commission on August 6, 2012 Registration No. 333-89234 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MEDTOX SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware |
|
| August 6, 2012 |
- POST EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 Post Effective Amendment No. 1 to Form S-3 As filed with the Securities and Exchange Commission on August 6, 2012 Registration No. 333-00827 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MEDTOX SCIENTIFIC, INC. (f/k/a EDITEK, INC.) (Exact name of registrant as specified in i |
|
| August 6, 2012 |
- POST EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 Post Effective Amendment No. 1 to Form S-1 As filed with the Securities and Exchange Commission on August 6, 2012 Registration No. 333-96609 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MEDTOX SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware |
|
| August 6, 2012 |
- POST EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 Post Effective Amendment No. 1 to Form S-3 As filed with the Securities and Exchange Commission on August 6, 2012 Registration No. 333-74562 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MEDTOX SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware |
|
| August 6, 2012 |
- POST EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 Post Effective Amendment No. 1 to Form S-3 As filed with the Securities and Exchange Commission on August 6, 2012 Registration No. 333-28783 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MEDTOX SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware |
|
| August 6, 2012 |
- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 Post-Effective Amendment No. 1 to Form S-8 As filed with the Securities and Exchange Commission on August 6, 2012 Registration No. 333-168922 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MEDTOX SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware |
|
| August 6, 2012 |
- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 Post-Effective Amendment No. 1 to Form S-8 As filed with the Securities and Exchange Commission on August 6, 2012 Registration No. 333-117199 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MEDTOX SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware |
|
| August 2, 2012 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) MEDTOX Scientific, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 584977201 (CUSIP Number) David Goldman GAMCO Investors, Inc. One Corporate Center Rye, New York 10580-1435 (914) 921-5000 (Name, Address and Telephone Number of Person Authorized to Re |
|
| August 1, 2012 |
LABCORP COMPLETES ACQUISITION OF MEDTOX Press Release, dated August 1, 2012 Exhibit 99.1 LABCORP COMPLETES ACQUISITION OF MEDTOX BURLINGTON, N.C. August 1, 2012 — Laboratory Corporation of America® Holdings (NYSE: LH) today announced the completion of its acquisition of MEDTOX Scientific, Inc. (NASDAQ: MTOX), effective July 31, 2012. At a special meeting held on July 31, 2012, MEDTOX’s stockholders approved the acquisition and the trans |
|
| August 1, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 July 30, 2012 (Date of earliest event reported) MEDTOX SCIENTIFIC, INC. (Exact Name of Registrant as Specified in its Charter) DELAWARE 1-11394 95-3863205 (State or other jurisdiction of Incorporation) (Commission File Numbe |
|
| August 1, 2012 |
SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION MEDTOX SCIENTIFIC, INC. ARTICLE I. EX-3.1 2 d388092dex31.htm SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Exhibit 3.1 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MEDTOX SCIENTIFIC, INC. ARTICLE I. Name The name of the corporation shall be MEDTOX Scientific, Inc. (the “Corporation”). ARTICLE II. Registered Office The registered office of the Corporation in the State of Delaware shall be located at 2711 Ce |
|
| August 1, 2012 |
MEDTOX SCIENTIFIC, INC. EFFECTIVE AS OF JULY 31, 2012 MEDTOX SCIENTIFIC, INC. EX-3.2 3 d388092dex32.htm AMENDED AND RESTATED BYLAWS OF MEDTOX SCIENTIFIC, INC Exhibit 3.2 MEDTOX SCIENTIFIC, INC. BYLAWS EFFECTIVE AS OF JULY 31, 2012 BYLAWS OF MEDTOX SCIENTIFIC, INC. 1. OFFICES 1.1 Registered Office The initial registered office of the Corporation in the State of Delaware shall be at 2711 Centerville Road, Suite 400 in Wilmington, County of New Castle, Delaware 19808. The name |
|
| July 26, 2012 |
FORM 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) (X) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2012 OR ( ) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period to Commission file number 1-11394 MEDTOX SCIENTIFIC, INC. (Exa |
|
| July 20, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [] Check the appropriate box: [] Preliminary Proxy Statement [] Confidential, For Use of the Commission Only (as permitted by Rule 14a-(e)(2)) [] Defin |
|
| July 20, 2012 |
Exhibit 99.1 MEDTOX SCIENTIFIC, INC. 402 WEST COUNTY ROAD D ST. PAUL, MINNESOTA 55112 SUPPLEMENT DATED JULY 20, 2012 TO DEFINITIVE PROXY STATEMENT FOR THE SPECIAL MEETING OF STOCKHOLDERS TO BE HELD JULY 31, 2012. This is a supplement to the proxy statement dated June 27, 2012 (the “Definitive Proxy Statement”) of MEDTOX Scientific, Inc., or MEDTOX, we, us, our or the Company. The Definitive Proxy |
|
| July 20, 2012 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2012 MEDTOX SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 1-11394 95-3863205 (State or other jurisdiction of incorporation) (Commission Fil |
|
| July 13, 2012 |
- DEFINITIVE ADDITIONAL MATERIALS Definitive Additional Materials UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 12, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2012 MEDTOX SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 1-11394 95-3863205 (State or other jurisdiction of incorporation) (Commission Fil |
|
| July 12, 2012 |
MEDTOX Scientific Announces Second Quarter Results Exhibit 99.1 MEDTOX Scientific, Inc. 402 West County Road D St. Paul, MN 55112 Contact: Janine Rivera (877) 715-7236 MEDTOX Scientific Announces Second Quarter Results ST. PAUL, Minn., July 12, 2012 — MEDTOX Scientific, Inc. (NASDAQ: MTOX) today announced results for the second quarter ended June 30, 2012. Highlights from the quarter compared to the prior-year period include: · Total revenues incr |
|
| July 12, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2012 MEDTOX SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 1-11394 95-3863205 (State or other jurisdiction of incorporation) (Commission Fil |
|
| July 12, 2012 |
MEDTOX Scientific Announces Second Quarter Results Exhibit 99.1 MEDTOX Scientific, Inc. 402 West County Road D St. Paul, MN 55112 Contact: Janine Rivera (877) 715-7236 MEDTOX Scientific Announces Second Quarter Results ST. PAUL, Minn., July 12, 2012 — MEDTOX Scientific, Inc. (NASDAQ: MTOX) today announced results for the second quarter ended June 30, 2012. Highlights from the quarter compared to the prior-year period include: · Total revenues incr |
|
| July 6, 2012 |
MTOX / / KOPP INVESTMENT ADVISORS LLC Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* MEDTOX SCIENTIFIC, INC. (Name of Issuer) Common Stock, $0.15 Par Value (Title of Class of Securities) 584977201 (CUSIP Number) June 29, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| July 3, 2012 |
MTOX / / GAMCO INVESTORS, INC. ET AL Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 MEDTOX Scientific, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 584977201 (CUSIP Number) David Goldman GAMCO Investors, Inc. One Corporate Center Rye, New York 10580-1435 (914) 921-5000 (Name, Address and Telephone Number of Person Authorized to Receive Notices and |
|
| July 2, 2012 |
Exhibit 99.1 SECOND AMENDMENT OF LEASE DATE: July 2, 2012 BETWEEN: ST. PAUL FIRE AND MARINE INSURANCE COMPANY, a Connecticut corporation, as successor by merger to St. Paul Properties, Inc., a Delaware corporation (“Lessor”) AND: Medtox Laboratories, Inc. a Delaware corporation (“Lessee”) LESSOR and LESSEE hereby agree as follows: 1 In this Second Amendment of Lease: a) "Premises" means that certa |
|
| July 2, 2012 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2012 MEDTOX SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 1-11394 95-3863205 (State or other jurisdiction of incorporation) (Commission File |
|
| June 28, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2012 MEDTOX SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 1-11394 95-3863205 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 28, 2012 |
Exhibit 99.1 MEDTOX Scientific, Inc. 402 West County Road D St. Paul, MN 55112 Contact: Janine Rivera (877) 715-7236 MEDTOX Announces Record Date and Meeting Date for Special Meeting of Stockholders in Connection with LabCorp Merger Agreement ST. PAUL, Minn., June 28, 2012 — MEDTOX Scientific, Inc. (NASDAQ: MTOX), announced in its definitive proxy statement on Schedule 14A that it has established |
|
| June 28, 2012 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2012 MEDTOX SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 1-11394 95-3863205 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 28, 2012 |
Exhibit 99.1 MEDTOX Scientific, Inc. 402 West County Road D St. Paul, MN 55112 Contact: Janine Rivera (877) 715-7236 MEDTOX Announces Record Date and Meeting Date for Special Meeting of Stockholders in Connection with LabCorp Merger Agreement ST. PAUL, Minn., June 28, 2012 — MEDTOX Scientific, Inc. (NASDAQ: MTOX), announced in its definitive proxy statement on Schedule 14A that it has established |
|
| June 27, 2012 |
Definitive Proxy Statement Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| June 15, 2012 |
Preliminary Proxy Statement Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| June 4, 2012 |
MEDTOX ANNOUNCES AGREEMENT TO JOIN LABCORP Exhibit 99.1 MEDTOX ANNOUNCES AGREEMENT TO JOIN LABCORP ST. PAUL, Minn., June 4, 2012 — MEDTOX Scientific, Inc. (NASDAQ: MTOX), a provider of high quality specialized laboratory testing services and on-site/point-of-collection testing (POCT) devices, today announced that it had entered into a definitive merger agreement with Laboratory Corporation of America® Holdings (NYSE: LH). Under the terms o |
|
| June 4, 2012 |
LABCORP ANNOUNCES AGREEMENT TO ACQUIRE MEDTOX SCIENTIFIC EX-99.2 6 ex99-2060412.htm EXHIBIT 99.2 Exhibit 99.2 LABCORP ANNOUNCES AGREEMENT TO ACQUIRE MEDTOX SCIENTIFIC BURLINGTON, N.C. June 4, 2012 — Laboratory Corporation of America® Holdings (NYSE: LH) and MEDTOX Scientific, Inc. (NASDAQ: MTOX), a provider of high quality specialized laboratory testing services and on-site/point-of-collection testing (POCT) devices, today announced that they had entere |
|
| June 4, 2012 |
MEDTOX ANNOUNCES AGREEMENT TO JOIN LABCORP Exhibit 99.1 MEDTOX ANNOUNCES AGREEMENT TO JOIN LABCORP ST. PAUL, Minn., June 4, 2012 — MEDTOX Scientific, Inc. (NASDAQ: MTOX), a provider of high quality specialized laboratory testing services and on-site/point-of-collection testing (POCT) devices, today announced that it had entered into a definitive merger agreement with Laboratory Corporation of America® Holdings (NYSE: LH). Under the terms o |
|
| June 4, 2012 |
Exhibit 10.2 280G EXCESS PAYMENT WAIVER WHEREAS, MEDTOX Scientific, Inc. (the “Company”), Laboratory Corporation of America Holdings (the “Parent”) and Mercer Acquisition Corp. (“Merger Sub”) are currently negotiating the terms of a Merger Agreement (the “Merger Agreement”) pursuant to which Merger Sub would merge with and into the Company, with the Company surviving as a wholly-owned subsidiary o |
|
| June 4, 2012 |
Exhibit 10.2 280G EXCESS PAYMENT WAIVER WHEREAS, MEDTOX Scientific, Inc. (the “Company”), Laboratory Corporation of America Holdings (the “Parent”) and Mercer Acquisition Corp. (“Merger Sub”) are currently negotiating the terms of a Merger Agreement (the “Merger Agreement”) pursuant to which Merger Sub would merge with and into the Company, with the Company surviving as a wholly-owned subsidiary o |
|
| June 4, 2012 |
Exhibit 10.1 280G EXCESS PAYMENT WAIVER WHEREAS, MEDTOX Scientific, Inc. (the “Company”), Laboratory Corporation of America Holdings (the “Parent”) and Mercer Acquisition Corp. (“Merger Sub”) are currently negotiating the terms of a Merger Agreement (the “Merger Agreement”) pursuant to which Merger Sub would merge with and into the Company, with the Company surviving as a wholly-owned subsidiary o |
|
| June 4, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2012 (June 3, 2012) MEDTOX SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 1-11394 95-3863205 (State or other jurisdiction of incorporation) ( |
|
| June 4, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2012 (June 3, 2012) MEDTOX SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 1-11394 95-3863205 (State or other jurisdiction of incorporation) ( |
|
| June 4, 2012 |
LABCORP ANNOUNCES AGREEMENT TO ACQUIRE MEDTOX SCIENTIFIC Exhibit 99.2 LABCORP ANNOUNCES AGREEMENT TO ACQUIRE MEDTOX SCIENTIFIC BURLINGTON, N.C. June 4, 2012 — Laboratory Corporation of America® Holdings (NYSE: LH) and MEDTOX Scientific, Inc. (NASDAQ: MTOX), a provider of high quality specialized laboratory testing services and on-site/point-of-collection testing (POCT) devices, today announced that they had entered into a definitive merger agreement und |
|
| June 4, 2012 |
Exhibit 10.1 280G EXCESS PAYMENT WAIVER WHEREAS, MEDTOX Scientific, Inc. (the “Company”), Laboratory Corporation of America Holdings (the “Parent”) and Mercer Acquisition Corp. (“Merger Sub”) are currently negotiating the terms of a Merger Agreement (the “Merger Agreement”) pursuant to which Merger Sub would merge with and into the Company, with the Company surviving as a wholly-owned subsidiary o |
|
| June 4, 2012 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER Dated as of June 3, 2012 among Laboratory Corporation of America Holdings, Mercer Acquisition Corp. and MEDTOX Scientific, Inc. TABLE OF CONTENTS Page ARTICLE I THE MERGER 1 Section 1.1 The Merger. 1 Section 1.2 Closing. 1 Section 1.3 Effective Time. 2 Section 1.4 Effects of the Merger. 2 Section 1.5 Certificate of Incorporation and Bylaws of the Surviving |
|
| June 4, 2012 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER Dated as of June 3, 2012 among Laboratory Corporation of America Holdings, Mercer Acquisition Corp. and MEDTOX Scientific, Inc. TABLE OF CONTENTS Page ARTICLE I THE MERGER 1 Section 1.1 The Merger. 1 Section 1.2 Closing. 1 Section 1.3 Effective Time. 2 Section 1.4 Effects of the Merger. 2 Section 1.5 Certificate of Incorporation and Bylaws of the Surviving |
|
| May 24, 2012 |
Exhibit 99.1 |
|
| May 24, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2012 MEDTOX SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 1-11394 95-3863205 (State or other jurisdiction of incorporation) (Commission File |
|
| May 24, 2012 |
EX-99.2 3 ex99-2052112.htm EXHIBIT 99.2 Exhibit 99.2 |
|
| April 26, 2012 |
FORM 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) (X) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2012 OR ( ) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period to Commission file number 1-11394 MEDTOX SCIENTIFIC, INC. (Ex |
|
| April 26, 2012 |
Exhibit 10.1 Executive Salaries for 2012 On February 13, 2012, the Compensation Committee of the Board of Directors of the Company (the “Committee”) approved 2012 base salaries for the executive officers, effective April 1, 2012, as set forth below: Executive Officer Title Salary Richard J. Braun President and Chief Executive Officer $390,000 Kevin J. Wiersma Vice President, Chief Administrative O |
|
| April 26, 2012 |
Exhibit 10.2 Target Financial Objectives for Fiscal Year 2012 under the Annual Incentive Plan and Long Term Incentive Plan On February 13, 2012, the Committee approved weighted target financial objectives for the Company’s 2012 Annual Incentive Plan and Long-Term Incentive Plan (LTIP). Awards will be based on the target payouts set forth below, which are expressed as a percentage of base salary. S |
|
| April 26, 2012 |
Exhibit 10.3 CEO EMPLOYMENT AGREEMENT THIS AGREEMENT dated January 1, 2007 by and between MEDTOX Scientific, Inc., a corporation (the "Company") and Richard J. Braun a resident of Minnesota ("Executive"). WHEREAS, the Company desires to employ Executive upon and subject to the terms and conditions set forth in this agreement, and Executive desires to render services for the Company on such terms a |
|
| April 17, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2012 MEDTOX SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 1-11394 95-3863205 (State or other jurisdiction of incorporation) (Commission Fi |
|
| April 17, 2012 |
MEDTOX® Scientific, Inc. First Quarter Conference Call April 12, 2012 Exhibit 99.1 MEDTOX® Scientific, Inc. First Quarter Conference Call April 12, 2012 Kevin Wiersma, MEDTOX - COO - Forensic Laboratory Operations & CFO: Good morning everyone. I’m Kevin Wiersma, chief operating officer of the MEDTOX Drugs-of-Abuse Laboratory Services division, and also CFO of the Company. Welcome to our first quarter conference call. Before Dick Braun, our CEO, begins our prepared p |
|
| April 12, 2012 |
MEDTOX SCIENTIFIC ANNOUNCES FIRST QUARTER RESULTS Exhibit 99.1 MEDTOX Scientific, Inc. 402 West County Road D St. Paul, MN 55112 Contact: Janine Rivera (877) 715-7236 MEDTOX SCIENTIFIC ANNOUNCES FIRST QUARTER RESULTS ST. PAUL, Minn., April 12, 2012 – MEDTOX Scientific, Inc. (Nasdaq:MTOX) today announced results for the first quarter ended March 31, 2012. Highlights from the quarter compared to the prior-year period include: · Total revenues incre |
|
| April 12, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2012 MEDTOX SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 1-11394 95-3863205 (State or other jurisdiction of incorporation) (Commission Fi |
|
| April 2, 2012 |
- DEFINITIVE ADDITIONAL MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [] Check the appropriate box: [] Preliminary Proxy Statement [] Confidential, For Use of the Commission Only (as permitted by Rule 14a-(e)(2)) [] Defin |
|
| April 2, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [] Check the appropriate box: [] Preliminary Proxy Statement [] Confidential, For Use of the Commission Only (as permitted by Rule 14a-(e)(2)) [X] Defi |
|
| March 8, 2012 |
MEDTOX SCIENTIFIC, INC. OUTSIDE DIRECTOR COMPENSATION Exhibit 10.35 MEDTOX SCIENTIFIC, INC. OUTSIDE DIRECTOR COMPENSATION Each non-employee Board member receives annual compensation in an amount determined by the Compensation Committee from time-to-time to be appropriate. Such compensation is currently established as set forth below: • The annual base compensation to be paid to non-employee Board members is $21,000. • $4,000 is added to the annual ba |
|
| March 8, 2012 |
EXHIBIT 21.1 SUBSIDIARIES OF REGISTRANT The Company has a wholly owned subsidiary, New Brighton Business Center, LLC. The subsidiary operates real estate property in which the Company locates its corporate headquarters. The Company has a wholly owned subsidiary, MEDTOX Diagnostics, Inc. in Burlington, North Carolina. The subsidiary manufactures and distributes diagnostic devices. The Company has a |
|
| March 8, 2012 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2011 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 1-11394 MEDTOX SCIENTIFIC, INC. (Exact name of Registrant as specified in its chart |
|
| February 15, 2012 |
Exhibit 99.1 MEDTOX® Scientific, Inc. Fourth Quarter Conference Call February 9, 2012 Kevin Wiersma, MEDTOX - COO - Laboratory Services Division and CFO: Good morning everyone. I’m Kevin Wiersma, chief operating officer of the MEDTOX Laboratory Services division, and also CFO of the Company. Welcome to our fourth quarter conference call. Before Dick Braun, our CEO, begins our prepared presentation |
|
| February 15, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2012 MEDTOX SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 1-11394 95-3863205 (State or other jurisdiction of incorporation) (Commission |
|
| February 10, 2012 |
MTOX / / Mairs & Power INC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Medtox Scientific, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 584977201 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 9, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2012 MEDTOX SCIENTIFIC, INC. (Exact name of registrant as specified in its charter) Delaware 1-11394 95-3863205 (State or other jurisdiction of incorporation) (Commission |
|
| February 9, 2012 |
MEDTOX SCIENTIFIC ANNOUNCES RESULTS FOR FOURTH QUARTER AND YEAR-END 2011 Exhibit 99.1 MEDTOX Scientific, Inc. 402 West County Road D St. Paul, MN 55112 Contact: Janine Rivera (877) 715-7236 MEDTOX SCIENTIFIC ANNOUNCES RESULTS FOR FOURTH QUARTER AND YEAR-END 2011 ST. PAUL, Minn., February 9, 2012 – MEDTOX Scientific, Inc. (Nasdaq:MTOX) today announced fourth quarter and year-end results for the periods ended December 31, 2011. Highlights from year-end compared to the pr |
|
| January 6, 2012 |
MTOX / / KOPP INVESTMENT ADVISORS LLC Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* MEDTOX SCIENTIFIC, INC. (Name of Issuer) Common Stock, $0.15 Par Value (Title of Class of Securities) 584977201 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
